Jeffrey D Klausner, MD
Infectious Disease · San Leandro
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 1 carrier
- Offices
- 4
- Since medical school
- 35 years
- Js Weill Medical College, Cornell University, 1991
Offices
4 locations · Bass Medical Group · 292 clinicians in this group
Looking this up.
Plans that list them
13 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Klausner’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G81840 · Current
Licensed to practise in California · since 1995 · expires 2027-06-30 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Infectious Disease
- American Board of Internal Medicine - Internal Medicine
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Removal of tissue | 1-10 | None |
Year by year
| 2022 | 17 | 22 | 72 | 0.70 | $5,052 | $2,252 |
| 2020 | 70 | 174 | 70 | 4.51 | $73,247 | $14,592 |
| 2019 | 80 | 245 | 68 | 2.92 | $124,030 | $23,681 |
| 2018 | 52 | 133 | 63 | 4.62 | $66,022 | $12,148 |
| 2017 | 87 | 255 | 66 | 4.22 | $122,814 | $25,602 |
| 2016 | 53 | 217 | 63 | 3.79 | $70,136 | $16,529 |
| 2015 | 50 | 149 | 66 | 4.13 | $50,035 | $13,505 |
| 2014 | 73 | 270 | 66 | 3.20 | $87,923 | $23,212 |
| 2013 | 66 | 199 | 64 | 3.17 | $69,370 | $18,219 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2020: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $8,017 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,962 | $177 |
2019: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $13,593 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,017 | $174 |
2018: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $5,410 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,886 | $169 |
2017: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $13,175 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,688 | $173 |
2016: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $9,196 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,090 | $172 |
2015: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $5,135 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,655 | $172 |
2014: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $12,519 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,025 | $167 |
2013: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $9,768 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,706 | $163 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 63 Part D prescriptions in 2021.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2021 | 63 | None | 0% (0) | 51% | $98,883 |
| 2020 | 139 | 11 | 0% (0) | 42% | $227,328 |
| 2019 | 159 | 12 | None | 48% | $186,411 |
| 2018 | 143 | None | None | 45% | $196,079 |
| 2017 | 178 | None | None | 34% | $109,851 |
| 2016 | 167 | 17 | None | 27% | $98,346 |
| 2015 | 229 | 12 | None | 34% | $221,508 |
| 2014 | 306 | 16 | None | 50% | $531,174 |
| 2013 | 43 | None | None | 28% | $18,519 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 2 drugs
| Biktarvy | 18 | $82,267 | $4,570 |
| Gabapentin | 11 | $62 | $6 |
2020: 4 drugs
| Biktarvy | 34 | $175,704 | $5,168 |
| Triumeq | 11 | $35,494 | $3,227 |
| Clonazepam | 12 | $209 | $17 |
| Lisinopril | 12 | $41 | $3 |
2019: 6 drugs
| Biktarvy | 34 | $108,872 | $3,202 |
| Triumeq | 12 | $37,036 | $3,086 |
| Ritonavir | 11 | $1,170 | $106 |
| Clonazepam | 12 | $168 | $14 |
| Alprazolam | 12 | $142 | $12 |
| Lisinopril | 12 | $41 | $3 |
2018: 2 drugs
| Biktarvy | 24 | $83,346 | $3,473 |
| Doxycycline Hyclate | 11 | $246 | $22 |
2017: 7 drugs
| Stribild | 13 | $38,670 | $2,975 |
| Triumeq | 12 | $33,477 | $2,790 |
| Genvoya | 12 | $33,331 | $2,778 |
| Acyclovir | 12 | $189 | $16 |
| Clonazepam | 12 | $163 | $14 |
| Alprazolam | 12 | $137 | $11 |
| Atorvastatin | 12 | $112 | $9 |
2016: 5 drugs
| Stribild | 15 | $41,519 | $2,768 |
| Triumeq | 11 | $27,025 | $2,457 |
| Clonazepam | 15 | $109 | $7 |
| Acyclovir | 12 | $50 | $4 |
| Alprazolam | 12 | $32 | $3 |
2015: 8 drugs
| Stribild | 30 | $77,400 | $2,580 |
| Fluconazole | 11 | $788 | $72 |
| Valacyclovir | 11 | $206 | $19 |
| Sulfamethoxazole-Trimethoprim | 21 | $190 | $9 |
| Acyclovir | 13 | $139 | $11 |
| Ibuprofen | 13 | $89 | $7 |
| Clonazepam | 12 | $61 | $5 |
| Lisinopril | 13 | $52 | $4 |
2014: 6 drugs
| Stribild | 23 | $57,896 | $2,517 |
| Truvada | 15 | $19,600 | $1,307 |
| Isentress | 16 | $18,308 | $1,144 |
| Norvir | 12 | $3,121 | $260 |
| Acyclovir | 13 | $290 | $22 |
| Lisinopril | 26 | $131 | $5 |
Money from drug and device companies
$3,306 in 2025
| 2025 | 5 | 7 | $3,197 | $3,306 |
| 2024 | 5 | 8 | $6,824 | $7,010 |
| 2023 | 4 | 5 | $16,600 | $16,600 |
| 2022 | 4 | 16 | $17,365 | $20,370 |
| 2021 | 2 | 2 | $6,408 | $6,408 |
| 2020 | 2 | 6 | $15,359 | $69,418 |
| 2019 | 2 | 5 | $2,900 | $3,176 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Roche Diagnostics International | None | $1,497 | 1 payment
|
| Visby Medical | Visby Medical Sexual Health Click Test | $850 | 1 payment
|
| BioFire Diagnostics | None | $850 | 1 payment
|
| Gilead Sciences | None | $90 | 3 payments
|
| Abbvie | Mavyret | $19 | 1 payment
|
See all 7 published payments
| Gilead Sciences | Meals · 2025-10-02 | None | $47 |
| Visby Medical | Consulting · 2025-09-26 | Visby Medical Sexual Health Click Test | $850 |
| Abbvie | Meals · 2025-08-11 | Mavyret | $19 |
| Gilead Sciences | Education · 2025-08-07 | None | $20 |
| Roche Diagnostics International | Consulting · 2025-06-23 | None | $1,497 |
| BioFire Diagnostics | Paid to speak or teach · 2025-04-09 | None | $850 |
| Gilead Sciences | Meals · 2025-02-03 | None | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,010
| Visby Medical | Visby Medical Sexual Health Click Test | $3,188 | 2 payments
|
| Abbott Laboratories | None | $2,250 | 1 payment
|
| BioFire Diagnostics | Biofire Respiratory Panel 2.1 | $850 | 1 payment
|
| La Jolla Pharmaceutical | None | $702 | 3 payments
|
| Gilead Sciences | None | $21 | 1 payment
|
2023: $16,600
| GlaxoSmithKline | None | $10,400 | 1 payment
|
| Abbott Laboratories | Id Now Instrument | $3,750 | 1 payment
|
| Visby Medical | Visby Medical Sexual Health Click Test | $1,700 | 2 payments
|
| BioFire Diagnostics | Biofire Respiratory Panel 2.1 | $750 | 1 payment
|
2022: $20,370
| Cepheid | Genexpert | $12,660 | 6 payments
|
| Paratek Pharmaceuticals | Nuzyra | $7,219 | 2 payments
|
| Abbvie | Mavyret | $375 | 5 payments
|
| Visby Medical | Visby Medical Sexual Health Click Test | $115 | 3 payments
|
2021: $6,408
| Roche Diagnostics | Cobas 4800 Ctng Test V20 | $3,500 | 1 payment
|
| GlaxoSmithKline | None | $2,908 | 1 payment
|
2020: $69,418
| Cepheid | Genexpert | $66,518 | 5 payments
|
| Roche Diagnostics | MD Cobas Instruments and Reagents | $2,900 | 1 payment
|
2019: $3,176
| Cepheid | Genexpert | $2,776 | 4 payments
|
| BioFire Diagnostics | Biofire Filmarray | $400 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · Study Name#Evaluation of Pregnant and Breastfeeding Womens Preferences and Attitudes Towards Long-Acting Pre-Exposure Prophylaxis# A Discrete Choice Experiment in South Africa and Botswana · 2024 | Their institution | $301,072 |
| Cepheid · Chlamydia Trachomatis, Neisseria Gonorrhoeae, and Trichomonas Vaginalis Screening and Treatment of Pregnant Women in Dhaka, Bangladesh · 2022 | Their institution | $173,400 |
| Merck Sharp & Dohme LLC · Evaluation of Pregnant and Breastfeeding Women'S Preferences and Attitudes Towards Long-Acting Pre-Exposure Prophylaxis A Discrete Choice Experiment in South Africa and Botswana · 2022 | Their institution | $129,031 |
| AbbVie, Inc. · Heor Study · 2019 | Their institution | $117,000 |
| Gen-Probe, Inc. · V10432-Hivops-Csp-02 · 2019 | Their institution | $84,863 |
| Gen-Probe, Inc. · A10810-Atvps-Csp · 2022 | Their institution | $60,853 |
| GlaxoSmithKline, LLC. · A Descriptive, Prospective, Multi-Country, Multicentre Study To Assess · 2022 | Their institution | $38,521 |
| GlaxoSmithKline, LLC. · 2021 | Their institution | $34,479 |
| GlaxoSmithKline, LLC. · A Descriptive, Prospective, Multi-Country, Multicentre Study To Assess · 2023 | Their institution | $33,324 |
| Gen-Probe, Inc. · V10432-Hivqps-Csp-02 · 2019 | Their institution | $29,817 |
| Gen-Probe, Inc. · Use the Hologic Test To Evaluate the Prevalence of Mycoplasma Genitalium · 2019 | Their institution | $23,740 |
| GlaxoSmithKline, LLC. · An Open, Multi-Centre Study To Evaluate the Sampling Method for the De · 2022 | Their institution | $5,000 |
| GlaxoSmithKline, LLC. · Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent · 2023 | Their institution | $4,785 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count · 2023 | Their institution | $1,580 |
Professional record
- NPI
- 1508973249
- Licence
- CA G81840California G81840: Current · expires 2027-06-30
- Trained
- Js Weill Medical College, Cornell University, 1991 · 35 years ago
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G818400, CA 1508973249
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Internal medicine (207R00000X)
- Mailing address
- 201 Dolores Ave, San Leandro, CA, 94577
- NPI first listed
- 2006-08-25
- NPI last updated
- 2025-12-16
- NPI record certified
- 2025-12-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1970 Mountain Blvd, Oakland, CA, 94611